Exhibit (a)(5)(C)
[PFE Letterhead]
August 26, 2011
Board of Directors
Icagen, Inc.
4222 Emperor Blvd., Suite 350
Durham, NC 27703
Ladies and Gentlemen:
In light of the scheduled August 31, 2011 expiration of our offer to purchase Icagen common stock and the communications by Merlin Nexus III, L.P. and New Leaf Ventures II, L.P., we thought it appropriate to reaffirm unambiguously, as we made clear when negotiating the merger agreement with you, that $6.00 per share is our best and final price. Pfizer will not pay more.
We expect Icagen stockholders will follow your unanimous recommendation and tender shares based on the recognition that $6.00 is a full and fair price. If a majority of the shares are not tendered, however, we still will not raise our offer.
Sincerely,
Douglas E. Giordano
Senior Vice President, Worldwide Business Development
cc:
Steven A. Wilcox
Ropes & Gray LLP
Prudential Tower
800 Boylston Street
Boston, MA 02199
